IatroQuest receives $4.8 million in financing

Guest Contributor
October 24, 2001

IatroQuest Corp has received a $4.8-million private placement to further develop its Bio-Alloy technology platform for the detection of biological and chemical agents. The financing was provided by Investissement Desjardins ($1.5 million), Business Development Bank of Canada ($1.5 million) T2C2 Bio 2000 ($1 million) and several private investors ($800,000). IatroQuest is a spin-off of the National Research Council, with the assistance of the Ottawa branch of Inno-Centre. The Ottawa firm’s Bio-Alloy is a ‘bio-photonic’ technology that uses biosensing modules (including micro-array biochip formats) to detect bacteria, viruses and toxins in real-time with a high degree of sensitivity. It will be aiming its OEM products at military, civilian and medical markets. Iatro-Quest has appointed Jean Bourbonnais as its new president and CEO, taking over from co-founders Dr David Armstrong (executive VP innovation and regulatory affairs) and Dr Martine Lafrance (chief technology officer)....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.